Which has stronger earnings & valuation, PBLS or MNKD?

MannKind has higher revenue and earnings than Parabilis Medicines. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Parabilis Medicines N/A N/A N/A N/A N/A MannKind $348.97M 3.46 $5.86M -$0.13 N/A

Does the media favor PBLS or MNKD?

In the previous week, MannKind had 9 more articles in the media than Parabilis Medicines. MarketBeat recorded 12 mentions for MannKind and 3 mentions for Parabilis Medicines. Parabilis Medicines' average media sentiment score of 0.92 beat MannKind's score of 0.53 indicating that Parabilis Medicines is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Parabilis Medicines 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MannKind 3 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to MNKD or ACAD?

In the previous week, MannKind had 9 more articles in the media than ACADIA Pharmaceuticals. MarketBeat recorded 12 mentions for MannKind and 3 mentions for ACADIA Pharmaceuticals. ACADIA Pharmaceuticals' average media sentiment score of 1.34 beat MannKind's score of 0.53 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MannKind 3 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive ACADIA Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, MNKD or CELC?

MannKind has higher revenue and earnings than Celcuity. MannKind is trading at a lower price-to-earnings ratio than Celcuity, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MannKind $348.97M 3.46 $5.86M -$0.13 N/A Celcuity N/A N/A -$177.04M -$4.30 N/A

Is MNKD or CELC more profitable?

Celcuity has a net margin of 0.00% compared to MannKind's net margin of -11.08%. MannKind's return on equity of -11.21% beat Celcuity's return on equity. Company Net Margins Return on Equity Return on Assets MannKind -11.08% -11.21% -6.31% Celcuity N/A -350.78% -41.54%

Does the media refer more to MNKD or CELC?

In the previous week, MannKind had 7 more articles in the media than Celcuity. MarketBeat recorded 12 mentions for MannKind and 5 mentions for Celcuity. Celcuity's average media sentiment score of 1.24 beat MannKind's score of 0.53 indicating that Celcuity is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MannKind 3 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Celcuity 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor EWTX or MNKD?

In the previous week, MannKind had 8 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 12 mentions for MannKind and 4 mentions for Edgewise Therapeutics. Edgewise Therapeutics' average media sentiment score of 1.55 beat MannKind's score of 0.53 indicating that Edgewise Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Edgewise Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive MannKind 3 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor MNKD or DYN?

In the previous week, Dyne Therapeutics had 23 more articles in the media than MannKind. MarketBeat recorded 35 mentions for Dyne Therapeutics and 12 mentions for MannKind. MannKind's average media sentiment score of 0.53 beat Dyne Therapeutics' score of 0.23 indicating that MannKind is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MannKind 3 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Dyne Therapeutics 10 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 5 Negative mention(s) 1 Very Negative mention(s) Neutral

MannKind (MNKD) Competitors

$3.75 -0.04 (-1.06%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$3.77 +0.02 (+0.43%)

As of 09/11/2026 07:59 PM Eastern

Compare

MNKD vs. PBLS, ACAD, CELC, EWTX, and DYN

Should you buy MannKind stock or one of its competitors? MannKind's main competitors and comparable companies include Parabilis Medicines (PBLS), ACADIA Pharmaceuticals (ACAD), Celcuity (CELC), Edgewise Therapeutics (EWTX), and Dyne Therapeutics (DYN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does MannKind compare to Parabilis Medicines?

Parabilis Medicines (NASDAQ:PBLS) and MannKind (NASDAQ:MNKD) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, profitability, valuation and dividends.

Parabilis Medicines has a net margin of 0.00% compared to MannKind's net margin of -11.08%. Parabilis Medicines' return on equity of 0.00% beat MannKind's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Parabilis Medicines	N/A	N/A	N/A
MannKind	-11.08%	-11.21%	-6.31%

In the previous week, MannKind had 9 more articles in the media than Parabilis Medicines. MarketBeat recorded 12 mentions for MannKind and 3 mentions for Parabilis Medicines. Parabilis Medicines' average media sentiment score of 0.92 beat MannKind's score of 0.53 indicating that Parabilis Medicines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Parabilis Medicines	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MannKind	3 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Parabilis Medicines presently has a consensus target price of $41.67, suggesting a potential upside of 12.98%. MannKind has a consensus target price of $8.34, suggesting a potential upside of 122.50%. Given MannKind's higher probable upside, analysts plainly believe MannKind is more favorable than Parabilis Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Parabilis Medicines	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
MannKind	2 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50

MannKind has higher revenue and earnings than Parabilis Medicines.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Parabilis Medicines	N/A	N/A	N/A	N/A	N/A
MannKind	$348.97M	3.46	$5.86M	-$0.13	N/A

49.6% of MannKind shares are owned by institutional investors. 2.6% of MannKind shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Parabilis Medicines and MannKind tied by winning 6 of the 12 factors compared between the two stocks.

How does MannKind compare to ACADIA Pharmaceuticals?

MannKind (NASDAQ:MNKD) and ACADIA Pharmaceuticals (NASDAQ:ACAD) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, earnings, dividends, valuation, risk and institutional ownership.

In the previous week, MannKind had 9 more articles in the media than ACADIA Pharmaceuticals. MarketBeat recorded 12 mentions for MannKind and 3 mentions for ACADIA Pharmaceuticals. ACADIA Pharmaceuticals' average media sentiment score of 1.34 beat MannKind's score of 0.53 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MannKind	3 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
ACADIA Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ACADIA Pharmaceuticals has a net margin of 33.42% compared to MannKind's net margin of -11.08%. ACADIA Pharmaceuticals' return on equity of 9.03% beat MannKind's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MannKind	-11.08%	-11.21%	-6.31%
ACADIA Pharmaceuticals	33.42%	9.03%	6.79%

MannKind has a beta of 1.1, suggesting that its share price is 10% more volatile than the broader market. Comparatively, ACADIA Pharmaceuticals has a beta of 0.86, suggesting that its share price is 14% less volatile than the broader market.

MannKind presently has a consensus price target of $8.34, indicating a potential upside of 122.50%. ACADIA Pharmaceuticals has a consensus price target of $34.36, indicating a potential upside of 23.47%. Given MannKind's higher probable upside, equities research analysts clearly believe MannKind is more favorable than ACADIA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MannKind	2 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50
ACADIA Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.78

49.6% of MannKind shares are held by institutional investors. Comparatively, 96.7% of ACADIA Pharmaceuticals shares are held by institutional investors. 2.6% of MannKind shares are held by company insiders. Comparatively, 26.2% of ACADIA Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

ACADIA Pharmaceuticals has higher revenue and earnings than MannKind. MannKind is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MannKind	$348.97M	3.46	$5.86M	-$0.13	N/A
ACADIA Pharmaceuticals	$1.07B	4.48	$391M	$2.22	12.54

Summary

ACADIA Pharmaceuticals beats MannKind on 13 of the 16 factors compared between the two stocks.

How does MannKind compare to Celcuity?

MannKind (NASDAQ:MNKD) and Celcuity (NASDAQ:CELC) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, dividends, analyst recommendations, valuation, earnings and media sentiment.

Celcuity has a net margin of 0.00% compared to MannKind's net margin of -11.08%. MannKind's return on equity of -11.21% beat Celcuity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MannKind	-11.08%	-11.21%	-6.31%
Celcuity	N/A	-350.78%	-41.54%

49.6% of MannKind shares are held by institutional investors. Comparatively, 63.3% of Celcuity shares are held by institutional investors. 2.6% of MannKind shares are held by company insiders. Comparatively, 13.3% of Celcuity shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

MannKind has higher revenue and earnings than Celcuity. MannKind is trading at a lower price-to-earnings ratio than Celcuity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MannKind	$348.97M	3.46	$5.86M	-$0.13	N/A
Celcuity	N/A	N/A	-$177.04M	-$4.30	N/A

MannKind has a beta of 1.1, meaning that its share price is 10% more volatile than the broader market. Comparatively, Celcuity has a beta of 0.19, meaning that its share price is 81% less volatile than the broader market.

MannKind presently has a consensus price target of $8.34, suggesting a potential upside of 122.50%. Celcuity has a consensus price target of $154.55, suggesting a potential upside of 85.20%. Given MannKind's higher probable upside, equities research analysts clearly believe MannKind is more favorable than Celcuity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MannKind	2 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50
Celcuity	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82

In the previous week, MannKind had 7 more articles in the media than Celcuity. MarketBeat recorded 12 mentions for MannKind and 5 mentions for Celcuity. Celcuity's average media sentiment score of 1.24 beat MannKind's score of 0.53 indicating that Celcuity is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MannKind	3 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Celcuity	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

MannKind beats Celcuity on 8 of the 14 factors compared between the two stocks.

How does MannKind compare to Edgewise Therapeutics?

Edgewise Therapeutics (NASDAQ:EWTX) and MannKind (NASDAQ:MNKD) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends, earnings and media sentiment.

Edgewise Therapeutics presently has a consensus target price of $50.33, indicating a potential upside of 13.36%. MannKind has a consensus target price of $8.34, indicating a potential upside of 122.50%. Given MannKind's higher probable upside, analysts plainly believe MannKind is more favorable than Edgewise Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edgewise Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
MannKind	2 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50

MannKind has higher revenue and earnings than Edgewise Therapeutics. MannKind is trading at a lower price-to-earnings ratio than Edgewise Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edgewise Therapeutics	N/A	N/A	-$167.79M	-$1.85	N/A
MannKind	$348.97M	3.46	$5.86M	-$0.13	N/A

In the previous week, MannKind had 8 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 12 mentions for MannKind and 4 mentions for Edgewise Therapeutics. Edgewise Therapeutics' average media sentiment score of 1.55 beat MannKind's score of 0.53 indicating that Edgewise Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Edgewise Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
MannKind	3 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Edgewise Therapeutics has a net margin of 0.00% compared to MannKind's net margin of -11.08%. MannKind's return on equity of -11.21% beat Edgewise Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Edgewise Therapeutics	N/A	-39.01%	-36.96%
MannKind	-11.08%	-11.21%	-6.31%

Edgewise Therapeutics has a beta of 0.32, indicating that its share price is 68% less volatile than the broader market. Comparatively, MannKind has a beta of 1.1, indicating that its share price is 10% more volatile than the broader market.

49.6% of MannKind shares are owned by institutional investors. 21.3% of Edgewise Therapeutics shares are owned by company insiders. Comparatively, 2.6% of MannKind shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

MannKind beats Edgewise Therapeutics on 9 of the 15 factors compared between the two stocks.

How does MannKind compare to Dyne Therapeutics?

MannKind (NASDAQ:MNKD) and Dyne Therapeutics (NASDAQ:DYN) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, risk, institutional ownership, profitability, valuation and earnings.

MannKind has higher revenue and earnings than Dyne Therapeutics. MannKind is trading at a lower price-to-earnings ratio than Dyne Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MannKind	$348.97M	3.46	$5.86M	-$0.13	N/A
Dyne Therapeutics	N/A	N/A	-$446.21M	-$3.33	N/A

In the previous week, Dyne Therapeutics had 23 more articles in the media than MannKind. MarketBeat recorded 35 mentions for Dyne Therapeutics and 12 mentions for MannKind. MannKind's average media sentiment score of 0.53 beat Dyne Therapeutics' score of 0.23 indicating that MannKind is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MannKind	3 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Dyne Therapeutics	10 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	5 Negative mention(s)	1 Very Negative mention(s)	Neutral

Dyne Therapeutics has a net margin of 0.00% compared to MannKind's net margin of -11.08%. MannKind's return on equity of -11.21% beat Dyne Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MannKind	-11.08%	-11.21%	-6.31%
Dyne Therapeutics	N/A	-64.30%	-50.33%

MannKind currently has a consensus price target of $8.34, indicating a potential upside of 122.50%. Dyne Therapeutics has a consensus price target of $32.17, indicating a potential upside of 76.64%. Given MannKind's higher possible upside, equities research analysts clearly believe MannKind is more favorable than Dyne Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MannKind	2 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50
Dyne Therapeutics	2 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.81

49.6% of MannKind shares are owned by institutional investors. Comparatively, 96.7% of Dyne Therapeutics shares are owned by institutional investors. 2.6% of MannKind shares are owned by company insiders. Comparatively, 9.5% of Dyne Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

MannKind has a beta of 1.1, suggesting that its share price is 10% more volatile than the broader market. Comparatively, Dyne Therapeutics has a beta of 1.08, suggesting that its share price is 8% more volatile than the broader market.

Summary

MannKind and Dyne Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

Get MannKind News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MNKD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MNKD vs. The Competition

Export

Metric	MannKind	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.21B	$3.84B	$7.12B	$12.72B
Dividend Yield	N/A	3.63%	2.56%	11.15%
P/E Ratio	-28.85	14.25	275.24	25.29
Price / Sales	3.46	1,473.06	655.99	98.94
Price / Cash	60.60	106.68	77.04	51.44
Price / Book	-22.06	15.12	10.33	6.20
Net Income	$5.86M	-$22.86M	$3.50B	$358.50M
7 Day Performance	-7.64%	-4.34%	-3.32%	-2.35%
1 Month Performance	-2.60%	-0.02%	-0.41%	-2.77%
1 Year Performance	-32.68%	40.64%	19.21%	7.63%

MannKind Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MNKD MannKind	2.9227 of 5 stars	$3.75 -1.1%	$8.34 +122.5%	-30.8%	$1.21B	$348.97M	N/A	400	Analyst Forecast Gap Down
PBLS Parabilis Medicines	2.6144 of 5 stars	$40.42 flat	$41.67 +3.1%	N/A	$4.99B	N/A	N/A	N/A	Positive News
ACAD ACADIA Pharmaceuticals	4.3854 of 5 stars	$28.02 flat	$34.36 +22.6%	+15.0%	$4.83B	$1.07B	12.62	510	Positive News
CELC Celcuity	2.6068 of 5 stars	$95.70 flat	$154.55 +61.5%	+45.3%	$4.68B	N/A	N/A	40	Positive News
EWTX Edgewise Therapeutics	2.8711 of 5 stars	$43.07 flat	$50.33 +16.9%	+202.7%	$4.68B	N/A	N/A	60	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MNKD) was last updated on 9/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MannKind (MNKD) Competitors

MNKD vs. PBLS, ACAD, CELC, EWTX, and DYN

How does MannKind compare to Parabilis Medicines?

Summary

How does MannKind compare to ACADIA Pharmaceuticals?

Summary

How does MannKind compare to Celcuity?

Summary

How does MannKind compare to Edgewise Therapeutics?

Summary

How does MannKind compare to Dyne Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MNKD vs. The Competition

MannKind Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MannKind (MNKD) Competitors

MNKD vs. PBLS, ACAD, CELC, EWTX, and DYN

How does MannKind compare to Parabilis Medicines?

Is PBLS or MNKD more profitable?

Does the media favor PBLS or MNKD?

Do analysts prefer PBLS or MNKD?

Which has stronger earnings & valuation, PBLS or MNKD?

Do institutionals & insiders have more ownership in PBLS or MNKD?

Summary

How does MannKind compare to ACADIA Pharmaceuticals?

Does the media refer more to MNKD or ACAD?

Is MNKD or ACAD more profitable?

Which has more volatility and risk, MNKD or ACAD?

Do analysts prefer MNKD or ACAD?

Do institutionals and insiders believe in MNKD or ACAD?

Which has preferable earnings & valuation, MNKD or ACAD?

Summary

How does MannKind compare to Celcuity?

Is MNKD or CELC more profitable?

Do insiders & institutionals have more ownership in MNKD or CELC?

Which has stronger earnings and valuation, MNKD or CELC?

Which has more volatility and risk, MNKD or CELC?

Do analysts recommend MNKD or CELC?

Does the media refer more to MNKD or CELC?

Summary

How does MannKind compare to Edgewise Therapeutics?

Do analysts recommend EWTX or MNKD?

Which has preferable earnings and valuation, EWTX or MNKD?

Does the media favor EWTX or MNKD?

Is EWTX or MNKD more profitable?

Which has more volatility & risk, EWTX or MNKD?

Do institutionals and insiders have more ownership in EWTX or MNKD?

Summary

How does MannKind compare to Dyne Therapeutics?

Which has better valuation and earnings, MNKD or DYN?

Does the media favor MNKD or DYN?

Is MNKD or DYN more profitable?

Do analysts prefer MNKD or DYN?

Do institutionals & insiders have more ownership in MNKD or DYN?

Which has more risk and volatility, MNKD or DYN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MNKD vs. The Competition

MannKind Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools